---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292121"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:58:06.341602+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission

## Summary
- All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.
- No dose-limiting toxicities observed; low-grade acute GVHD in 60% of patients.
- Gamma-delta T cells expanded and persisted >365 days post single dose; dose response shows 48.9x greater at day 60 for DL 2 vs HSCT alone.
- Two patients progression-free for over 3 years; individual follow-up ranges 4.9 to 42.7 months.

## SEC filing metadata
- accession: 0001193125-23-292121
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/0001193125-23-292121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/d747940d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292121
- JSON: https://secwatch.observer/filing/0001193125-23-292121.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.